protein, gp120, facilitating binding to one of the coreceptors, CCR5 or CXCR4, leading to fusion of viral and cell membranes and viral entry [4, [7] [8] [9] [10] [11] . Viruses may be exclusive in their use of coreceptors, being CCR5 tropic (R5 tropic), CXCR4 tropic (X4 tropic), or dual tropic, which indicates the ability to use either CXCR4 or CCR5 as a coreceptor [12] . X4-tropic and dual-tropic strains typically emerge later in the disease in 30%-50% of infected individuals [13, 14] . The presence of CXCR4-using virus (X4 virus) is associated with an accelerated decrease in CD4 cell count and disease progression [13, [15] [16] [17] .
Maraviroc, the first CCR5 antagonist, has been approved for treatment-experienced patients infected with HIV resistant to multiple antiretroviral agents [18] [19] [20] . In vivo HIV is thought to use only CCR5 and CXCR4, which makes synergy between antagonists likely. Combinations of entry inhibitors have been noted to be synergistic in vitro [21] [22] [23] . For these reasons, there is a keen interest in the development of agents that are capable of blocking X4 virus entry.
AMD11070 (also known as AMD070 or 070) is a novel, orally bioavailable, selective, and reversible small-molecule antagonist of CXCR4. It has been shown to inhibit replication of X4-tropic HIV in PBMCs and other cell lines in vitro [24] . In vitro, it inhibits the binding of the natural chemokine ligand, SDF1a, to CXCR4 and inhibits SDF-1a-induced signaling mechanisms [25] .
A previously investigated small-molecule CXCR4 inhibitor, AMD3100, demonstrated antiviral activity in HIV-infected patients in a phase 2 study in which it was administered by 24-h continuous intravenous infusion for 10 days [26] . One participant harboring only X4 virus showed a reduction in HIV RNA level of copies/mL, and 10 of 14 patients 0.87 Ϫ log 10 harboring dual-or mixed-tropic viruses showed reductions in the population of X4 virus after treatment (S. Fransen, G. Bridger, J. M. Whitcomb, unpublished data). This observed activity validated blockade of the CXCR4 receptor as an antiviral target.
X4-tropic viruses are found at increasing frequency as the CD4 cell count decreases [14, 27] . Their presence may be unmasked by antiretroviral therapy, particularly with CCR5 antagonists [28] . Because most patients who harbor X4-tropic viruses also carry R5-tropic viruses, the activity of an X4 antagonist as monotherapy is not expected to be reflected by a meaningful change in HIV load. Rapid throughput coreceptor tropism assays, such as Trofile (Monogram Biosciences), which uses luciferase to produce a luminous readout to indicate the levels of X4 or R5 viruses, provides a semiquantitative and qualitative report of viral tropism [29] . For this reason, reduction in X4 virus population by the Trofile assay was chosen as a primary efficacy outcome for the investigation of X4 antagonists. This screening technology does not distinguish between dual-tropic viruses and mixtures of R5-and X4-tropic viruses and, thus, refers to a dual or mixed virus category if the sample was not exclusively R5 or X4 tropic.
The X4 Antagonist Concept Trial (XACT) evaluated the safety and antiviral activity of AMD11070 monotherapy for 10 days in HIV-infected individuals harboring X4-tropic viruses. The primary end points were the proportion of patients who had a reduction in their X4-tropic virus level of у1 Ϫ log 10 relative luminescence units (rlu), as determined by the Trofile assay, and the changes in X4 virus population from baseline to day 10. We also assessed the relationship between pharmacokinetic parameters and viral response, changes in CD4 cell count, plasma HIV load, WBC count, and CD34 cell count.
PATIENTS AND METHODS
Study setting and patient population. XACT was a dualcenter, open-label, single-arm, dose-finding study conducted at Chelsea Westminster Hospital (London, United Kingdom), and Orlando Immunology Center (Orlando, FL). The study protocol was approved by the St. Mary's Research Ethics Committee and the Sterling Institutional Review Board and was conducted in accordance with the Declaration of Helsinki. Written consent was obtained from all study participants before any study procedures were performed. This study was registered at http://clinicaltrials.gov (NCT00361101).
HIV-infected patients aged у18 years who had a CD4 cell count р200 cells/mm 3 and an HIV-1 RNA level у5000 copies/ mL were included. Treatment-experienced patients receiving antiretroviral therapy were required to have a washout period of at least 14 days before study entry to limit the risk of drugdrug interactions between established antiretroviral agents and the study drug. Patients were required to demonstrate the presence of X4-tropic virus or dual-tropic virus with an X4 virus population of у2000 rlu in luciferase activity in the Trofile assay [29] . Because of the potential of drug-drug interactions, use of any CYP-3A4 inhibitors or inducers, P-glycoprotein inhibitor or inducers, and CYP-2D6 and CYP-2C8 substrates was prohibited in the study.
Study design. Eligible participants enrolled in the study for the first dose cohort were administered AMD11070 monotherapy (200 mg twice daily on an empty stomach) for 10 consecutive days. All daily doses were administered once in the morning and once in the evening. Participants were allowed to resume or start antiretroviral therapy on day 11.
At study entry, on day 5, and on day 10, samples were collected for determination of CD4 and CD8 cell counts, HIV-1 RNA level, and HIV-1 coreceptor tropism (Trofile) and for clinical safety laboratory evaluations. In addition, samples were collected at study entry and on day 10 for AMD11070 susceptibility testing (results not reported). Monitoring of adverse events (AEs), concomitant medications, and vital signs; symptom-directed physical examination; and electrocardiography were performed daily throughout the study period and during follow-up visits. The AEs and laboratory abnormalities were categorized in accordance with the National Institute of Allergy and Infectious Diseases Division of AIDS Table for Grading Severity of Adult Adverse Experiences.
A 24-h pharmacokinetics profile was obtained by intensive blood testing for levels of AMD11070 on day 10 at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 13, 14, 16, 18 , and 24 h after the secondto-last dose (morning dose) of AMD11070. Urine pharmacokinetic analysis was also performed on day 10. All pharmacokinetic samples were collected daily before the morning dose.
Up to 4 dose cohorts were planned. Only the first dose cohort is reported herein. Because of histologic changes in the liver observed in long-term animal toxicity studies, this study has been halted.
Data analysis. The primary objectives of this study were a Baseline is the geometric mean value at screening and at study entry. b Viral assay results at study entry. c Efficacy data from this patient were considered to be nonevaluable because of disparate coreceptor tropism results at screening and at study entry.
to determine the safety and antiviral activity of AMD11070 administered for 10 days, to determine the proportion of patients who had a reduction in their X4-tropic virus level of у rlu, and to describe changes in X4 virus population 1 Ϫ log 10 during the 10 days of AMD111070 treatment. The geometric mean of the pre-entry and entry measurements was used to define baseline. The proportion of patients who responded to therapy (defined as those who had a reduction in X4-tropic virus level of у rlu at any time during the 10 days of 1 Ϫ log 10 treatment) was evaluated using descriptive statistics. Secondary objectives included receptor tropism, pharmacokinetic parameters, plasma HIV-1 RNA level, and CD4 cell count (absolute and percentage). Safety parameters included clinical and laboratory evaluations and the monitoring of AEs and concomitant medications. Plasma AMD11070 concentrations were determined using a validated high-performance liquid chromatography tandem mass spectrometry method described elsewhere [30] . Pharmacokinetic parameters were calculated using WinNonlin, version 4.1 (Pharsight).
RESULTS

Patient population.
Ten patients (9 men and 1 woman) aged 34-50 years (median age, 41 years) were enrolled in the study. There were 6 white patients (60%), 2 Hispanic patients (20%), 1 African American patient (10%), and 1 patient (10%) with mixed heritage. Table 1 shows the baseline characteristics of the study participants. One patient was considered to be nonevaluable for efficacy outcomes because of disparate coreceptor tropism results at screening and study entry. This patient was included in all safety and pharmacokinetic evaluations. In the 9 patients evaluated for efficacy, the median baseline CD4 cell count was 173 cells/mm 3 (range, 1-342 cells/mm 3 ), and the median HIV RNA level was 91,447 copies/mL (range, 16,402-852,432 copies/mL). At study entry, 7 patients had dual or mixed virus, 2 had X4 virus only, and 1 had R5 virus only (this patient was excluded from the efficacy analysis). The median baseline X4 virus and R5 virus levels in the 9 evaluable patients were 3.85 log 10 rlu (range, 3.20-5.88 log 10 rlu) and 4.94 log 10 rlu (range, 1.74-5.88 log 10 rlu), respectively. With the exception of 1 patient mentioned here, similar values were observed at screening and at baseline for HIV-1 RNA, X4, and R5 levels.
Safety. All 10 enrolled patients were included in all safety analyses. The only serious AE reported was seizure in a patient with known epilepsy who had discontinued antiepileptic therapy. This AE was considered to be unrelated to the study drug. A total of 6 study drug-related AEs were reported by 5 patients. All but 1 drug-related AE were of grade 1 severity. Diarrhea was the most frequently reported drug-related AE (in 3 [50%] of 6 patient); all cases were of grade 1 severity. Headache (grade 2), flatulence, and dizziness were all reported once. No laboratory abnormalities of grade 1 or higher were observed. There were no clinically significant out-of-range safety laboratory findings noted.
Reduction in X4-tropic virus level. Figure 1 shows the virologic response of patients. Because of dosing error, patients 1 and 2 received only 100 mg of AMD11070 twice daily rather than the protocol-defined dose of 200 mg. Three patients met the primary end point of a reduction in X4 virus population of у rlu. Two patients achieved a reduction of 1 Ϫ log 10 
NOTE. DM, dual-tropic or mixed viruses; NA, not available; R5, R5-tropic virus only; X4, X4-tropic virus only. Boldface type indicates patients who did not respond to therapy (patients with a reduction in X4 virus population of ! relative luminescence units). 1 Ϫ log 10 a The day 1 sample was obtained before administration of the first dose of AMD11070. was 1.9 log 10 rlu in a patient who received the 100-mg dose.
One patient demonstrated an X4 population reduction of 0.72 log 10 rlu on day 10 but showed a reduction of 1.30Ϫlog 10 rlu on day 5. Therefore, when the maximal reduction during treatment was considered, 4 patients showed a reduction in X4 virus population of у rlu. The X4 virus populations of all 1 Ϫ log 10 patients who responded to therapy increased after the completion of AMD11070 treatment, returning to close to baseline levels by day 30. In contrast, the R5 virus level remained unchanged during the study period. Overall, the 9 evaluable patients demonstrated a median change in X4 virus population of Ϫ0.22 log 10 rlu (range, Ϫ1.90 to 0.23 log 10 rlu) from baseline to the end of treatment.
Change in coreceptor tropism. Tropism, as determined by the Trofile assay, is indicated in table 2. Most evaluable patients (7 of 9) were reported as having dual-or mixed-tropic virus at study entry (day 1). Patients with dual or mixed tropism at study entry included all 4 patients who responded to therapy and 3 of the 5 patients who did not respond to therapy. Two of the 5 patients who did not respond to therapy had X4 tropism at study entry.
Three of 4 patients who responded to therapy demonstrated a shift from dual or mixed tropism to R5 tropism during treatment. The shift to R5 tropism reverted back to dual or mixed tropism after the cessation of treatment by day 30 in these 3 patients who responded to therapy. Conversely, all but 1 patient who did not respond to therapy maintained the same tropism throughout the study. One patient who did not respond to therapy who had X4 tropism at study entry showed a shift to dual or mixed tropism on day 5 but returned to X4 tropism by day 17.
Other efficacy parameters. The HIV load, CD4 cell count, R5 virus level, and WBC count in the 9 evaluable patients are presented in table 3. No significant changes in HIV-1 RNA level, CD4 cell count, R5 virus level, and WBC count were observed during the treatment period. One patient (patient 3; who did not respond to therapy) demonstrated a reduction in HIV load of 11Ϫlog 10 copies/mL, whereas another patient (patient 8; who responded to therapy) showed an increase in HIV load of 1 copies/mL on day 10. No significant changes 1 Ϫ log 10 in HIV-1 RNA level were observed in other patients. The R5 virus level in patients did not change significantly, regardless of the patient's response to the X4 inhibitor, which suggests that the suppression of X4 virus by AMD11070 did not result in an increase in R5 virus levels.
Pharmacokinetic parameters. AMD11070 was well absorbed after oral administration and cleared from plasma in a biexponential manner. The ratios of 100-to 200-mg maximum concentration of drug and area under the curve at 0-24 h were 3.7 and 5.8, respectively; this suggests a greater than proportional increase in exposure with dose doubling (table 4). Accumulation of AMD11070 was indicated by the observed increases in trough concentrations (data not shown). The increasing trend in trough plasma concentrations suggests that steady state may not be achieved after 10 days of administration of a twice-daily regimen. The median minimum concentration of drug on day 10 was 82.0 ng/mL (range, 17-210 ng/mL) in the 200-mg dose group, which was close to the protein-adjusted in vitro effective concentration to inhibit 90% of virus (∼100 ng/mL) of AMD11070 against X4-tropic virus in PBMCs [24] ; this suggests that this dose would be associated with antiviral activity in vivo. However, no relationship was observed between a The day 1 sample was obtained before the administration of the first dose of AMD11070. b These patients received 100 mg of AMD11070 twice daily.
AMD11070 pharmacokinetic parameters and X4 virus population reduction on day 10 (table 4) .
DISCUSSION
This study confirms CXCR4 as a target for antiretroviral drug development and establishes the activity of AMD11070. In the XACT study, 4 of 9 evaluable patients demonstrated a reduction in X4 virus population of у rlu during 10-day mono-1 Ϫ log 10 therapy with AMD11070, a CXCR4 antagonist. The activity of AMD11070 in suppressing X4 virus was supported by the observation of a tropism shift from dual or mixed virus to R5 virus only in 3 of 4 patients who responded to therapy. In all cases, the tropism reverted to the baseline level after the completion of AMD11070 treatment.
Because the Trofile assay cannot distinguish between dualtropic or mixed-tropic viruses, the reason that 1 patient who responded to therapy (patient 4) remained in the dual or mixed virus category throughout the study could be because this patient harbored dual-tropic virus, which could use CCR5 as coreceptor while CXCR4 was being blocked, rather than a mixture of X4-and R5-tropic viruses. One patient who did not respond to therapy demonstrated a shift from X4 to dual or mixed tropism during treatment, which reverted after the completion of treatment. It is possible that the apparent shift from X4 to dual or mixed tropism was a result of a selected suppression of the predominantly majority X4 virus by the study drug, which led to the subsequent "unmasking" of the minor R5 virus. Of note, this patient also showed the highest X4 virus population at study entry.
No clear pharmacokinetic/pharmacodynamic relationship was demonstrated with overlapping plasma exposures of AMD11070 in patients who did and did not respond to therapy. It is likely that the exposures achieved in this study represent the lower end of a dose-response curve, where variability in response may be expected.
Viral factors, such as the proportion of X4 virus and the overall viral load at study entry, may contribute to the activity at the doses studied. All patients who responded to therapy had relatively low X4 virus populations (!4 log 10 rlu) at study entry. This finding may reflect that these patients had true mixtures of X4 and R5 virus, whereas some individuals with high X4 virus populations might have possessed dual-tropic virus. However, 1 of the patients who did not respond to therapy (patient 7) also had a similarly low X4 virus population, which suggests that other factors determine activity. We observed no relationship between CD4 cell count and X4 virus response. Preliminary AMD11070 susceptibility data on samples collected at study entry revealed no relationship between the susceptibility of the patient's isolate and the efficacy of AMD11070 in each patient.
The lack of changes in HIV RNA level, both overall and among patients who responded to therapy, was anticipated and echoed findings from the proof-of-concept study with the CXCR4 antagonist AMD3100 [26] . In the AMD3100 study, no significant reduction in HIV load was observed, despite a retrospective analysis that demonstrated that 10 of 14 patients who harbored dual-or mixed-tropic viruses had a reduction in their X4 virus population [31] . Conversely, although leukocytosis was observed in healthy volunteers and HIV-infected patients receiving AMD3100, as well as in healthy volunteers receiving AMD11070 [30, 32] , it was not observed in HIVinfected patients in our study of AMD11070. This observation may be a reflection of AMD11070 and AMD3100 belonging to different chemical classes with different clinical pharmacologic features [33, 34] , although they share the same cellular target. The apparent lack of leukocytosis in HIV-infected patients could be attributable to the differences in the times that samples were obtained and the timing of maximum pharmacologic responses. The use of X4 virus population is not a conventional means of assessing activity but is one that reflects emerging diagnostic technology and the novel host receptor targeted by AMD11070. The consistency of R5 virus levels in patients during the study confirms the activity and specificity of AMD11070 and also validates the use of X4 virus population to assess the activity of CXCR4 antagonists. The sensitivity of this version of Trofile to detect minority species in mixed viral populations is 5%-10%. This frequency also varies, depending on the infectivity of the minority species [29] . The use of the assay as a screening tool has been validated in the development program for the CCR5 antagonist maraviroc [2] . However, this test is unable to differentiate between an absolute and relative change in viral populations, and the quantitative unit rlu is not a measure of viral composition (X4 and R5 percentage). For the purpose of this study, this assay allowed an estimate of activity and, importantly, served as a bridge to the use of the conventional measurement HIV RNA level in a study that allows the combination of AMD11070 and other antiretroviral agents. The frequency of the tropism shift and the actual clinical implications remain uncertain at this time. X4 and dual or mixed viruses are associated with a more rapid decrease in CD4 cell count and risk of clinical progression, compared with R5 viruses alone [35] ; thus, suppression of these viruses can potentially be of clinical importance.
The clinical development of AMD11070 has been halted because of observed histologic findings in the liver in long-term animal studies. AMD11070 exposures associated with toxic effects in the animal studies are in the range of those associated with clinical doses tested to date. Human studies, to date, have shown no findings (alanine aminotransferase, aspartate aminotransferase, and total bilirubin levels) to suggest hepatic toxic effects after 10 days of AMD11070 treatment. If additional studies can confirm the safety of AMD11070 for long-term use in humans, administration of AMD11070 in combination with a CCR5 antagonist can be expected, in the presence or absence of an optimized backbone regimen. In such cases, the clinical benefits of a CXCR4 antagonist can be truly assessed.
The findings of the AMD11070 XACT study demonstrate the activity of this first in class oral CXCR4 antagonist against X4-tropic HIV. The results also show that the study drug was well tolerated, with no serious safety concerns. Further preclinical and clinical assessments are needed to fully examine the potential of AMD11070 for the treatment of HIV infection.
